Have breakfast with top biopharma newsmakers
Turning Point: Access and Affordability in a New Era of Medicine
2017 is shaping up as a potential turning point in the public debate over drug affordability and access in the United Sates. Should companies self-regulate on pricing, as some have discussed? Should biopharma fight every new proposal? How will the debate influence the companies researching new drugs in the pipeline? We’ll hear from these biopharma CEOs and leaders how they plan to deliver innovative therapies in this new era.
EVP and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson
Editor, Endpoints News